Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744628 | 1.00 | CRHR1 (0.37) | CRHR1HPGDMEN1KMT2ALMNA | |
| SCHEMBL17532270 | 1.00 | CRHR1 (0.37) | CRHR1HPGDMEN1KMT2ALMNA | |
| SCHEMBL17532272 | 0.95 | MEN1 (0.36) | CRHR1HPGDMEN1KMT2ALMNA | |
| SCHEMBL15825228 | 0.90 | HTR1A (0.38) | CRHR1HPGDMEN1KMT2ALMNA | |
| SCHEMBL20843208 | 0.90 | MEN1 (0.36) | CRHR1HPGDMEN1KMT2ALMNA | |
| SCHEMBL15823941 | 0.85 | HSD17B10 (0.33) | HPGDMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL15839083 | 0.83 | MEN1 (0.40) | CRHR1HPGDMEN1KMT2ALMNA | |
| SCHEMBL19270328 | 0.82 | LPAR1 (0.35) | HPGDMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL2712918 | 0.82 | CRHR1 (0.37) | CRHR1HPGDMEN1KMT2ALMNA | |
| SCHEMBL29411892 | 0.81 | TAS1R3 (0.33) | CRHR1MEN1KMT2ASMN1; SMN2TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935289-B1 | DERIVATIVES OF BISACYLPHOSPHINIC ACID, THEIR PREPARATION AND USE AS PHOTOINITIATORS | IGM GROUP B V (NL) | 2019-06-26 | — | — | EP | disclosed |
| EP-3459957-A1 | DERIVATIVES OF BISACYLPHOSPHINIC ACID, THEIR PREPARATION AND USE AS PHOTOINITIATORS | IGM Group B.V. (NL) | 2019-03-27 | — | — | EP | disclosed |
| US-10040810-B2 | Derivatives of bisacylphosphinic acid, their preparation and use as photoinitiators | BASF SE (DE) | 2018-08-07 | — | — | US | disclosed |
| US-10040810-B2 | Derivatives of bisacylphosphinic acid, their preparation and use as photoinitiators | BASF SE (DE) | 2018-08-07 | — | — | US | disclosed |
| US-10040810-B2 | Derivatives of bisacylphosphinic acid, their preparation and use as photoinitiators | BASF SE (DE) | 2018-08-07 | — | — | US | disclosed |
| US-20160039851-A1 | DERIVATIVES OF BISACYLPHOSPHINIC ACID, THEIR PREPARATION AND USE AS PHOTOINITIATORS | IGM GROUP B.V. (NL) | 2016-02-11 | — | — | US | disclosed |
| US-20160039851-A1 | DERIVATIVES OF BISACYLPHOSPHINIC ACID, THEIR PREPARATION AND USE AS PHOTOINITIATORS | IGM GROUP B.V. (NL) | 2016-02-11 | — | — | US | disclosed |
| US-20160039851-A1 | DERIVATIVES OF BISACYLPHOSPHINIC ACID, THEIR PREPARATION AND USE AS PHOTOINITIATORS | IGM GROUP B.V. (NL) | 2016-02-11 | — | — | US | disclosed |
| EP-2935289-A1 | DERIVATIVES OF BISACYLPHOSPHINIC ACID, THEIR PREPARATION AND USE AS PHOTOINITIATORS | BASF SE (DE) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014095724-A1 | DERIVATIVES OF BISACYLPHOSPHINIC ACID, THEIR PREPARATION AND USE AS PHOTOINITIATORS | BASF SE (DE) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039851-A1 | DERIVATIVES OF BISACYLPHOSPHINIC ACID, THEIR PREPARATION AND USE AS PHOTOINITIATORS | ARSA, ACSL6, RER1 | CRHR1 3228/4885HPGD 4526/4885MEN1 1781/4885 |
| US-10040810-B2 | Derivatives of bisacylphosphinic acid, their preparation and use as photoinitiators | ARSA, RER1, ACSL6 | CRHR1 3808/4885HPGD 4618/4885MEN1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.